NIPRO Corporation 8086
TSE · Japan · Gesundheitstechnologie
¥1.350,50-18,00 (-1,32 %)
Markt geschlossen· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geschlossen· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
The global vascular access device market is projected to grow from USD 6.27 billion in 2026 to USD 8.68 billion by 2031, at a 6.7% CAGR. Growth is driven by rising cancer, cardiovascular and kidney disease cases, increased IV therapies and advances in safety-engineered, antimicrobial and ultrasound-guided devices. Peripheral devices and drug administration will see strong growth, while clinics and ambulatory care centers gain adoption. Asia Pacific is forecast to record the highest CAGR. Key pla
Examines STEMIRAC market potential, clinical development, regulatory milestones, competitive positioning, pricing, reimbursement and sales forecasts across seven major pharmaceutical marketsDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "STEMIRAC Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of STEMIRAC for traumatic spinal cord injury, including historical performance, current utilization and
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.